Favorable Impact of Virological Response to Highly Active Antiretroviral Therapy on Survival in Patients with AIDS-related Lymphoma
José‐Tomás Navarro(Universitat Autònoma de Barcelona), Evarist Feliú(Universitat Autònoma de Barcelona), Albert Oriol(Institut Català d'Oncologia), Joan Romeu(Hospital Universitari Germans Trias i Pujol), Fuensanta Millá, Javier Grau, Blanca Xicoy(Hospital Universitari Germans Trias i Pujol), Montserrat Batlle(Centro de Investigación en Red en Enfermedades Cardiovasculares), Josep‐María Ribera(Universitat Autònoma de Barcelona), Guillem Sirera, José Luís Mate(Universitat Autònoma de Barcelona)
Cited by 20
Related Papers
Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study
|The Lancet Oncology|2014|1.3k
Teclistamab in Relapsed or Refractory Multiple Myeloma
|New England Journal of Medicine|2022|1.2k
Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma
|New England Journal of Medicine|2023|719